Portfolio Holdings Detail for ISIN IE00BYZK4776

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE

Holdings detail for FATE

Show aggregate FATE holdings

News associated with FATE

Fate Therapeutics (NASDAQ:FATE) & Cyclerion Therapeutics (NASDAQ:CYCN) Head-To-Head Analysis

Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Risk & Volatility Fate Therapeutics has a […] - 2025-08-29 02:14:49

Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.83

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 […] - 2025-06-24 02:54:47

Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Squarepoint Ops LLC grew its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 154.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,295 shares of the biopharmaceutical company’s stock after acquiring an additional 20,805 […] - 2025-06-11 05:08:50

Bank of America Corp DE Reduces Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

Bank of America Corp DE lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 64.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 304,129 shares of the biopharmaceutical company’s stock after selling 550,066 shares during the quarter. Bank of America Corp DE’s holdings in Fate Therapeutics were […] - 2025-06-11 04:14:58

Graham Capital Management L.P. Buys New Shares in Fate Therapeutics, Inc. (NASDAQ:FATE)

Graham Capital Management L.P. bought a new stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 22,342 shares of the biopharmaceutical company’s stock, valued at approximately $37,000. Other large investors […] - 2025-05-20 05:40:49

D. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

D. E. Shaw & Co. Inc. lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 54.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,536,633 shares of the biopharmaceutical company’s stock after selling 1,841,017 shares […] - 2025-05-20 04:56:58

Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Hsbc Holdings PLC grew its stake in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 22.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 109,422 shares of the biopharmaceutical company’s stock after purchasing an additional 19,706 shares during the quarter. Hsbc […] - 2025-05-12 04:56:49

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $5.43 Consensus PT from Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average […] - 2025-05-05 03:13:09

CANADA LIFE ASSURANCE Co Has $35,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

CANADA LIFE ASSURANCE Co trimmed its position in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 53.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,267 shares of the biopharmaceutical company’s stock after selling 24,365 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Fate Therapeutics were worth $35,000 at the end […] - 2025-05-01 05:50:46

Marshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)

Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company’s stock, valued at approximately $846,000. Marshall Wace LLP owned approximately 0.45% of Fate […] - 2025-05-01 04:53:01

Cerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Cerity Partners LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 4,953.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 823,134 shares of the biopharmaceutical company’s stock after purchasing an additional 806,846 shares during the period. Cerity Partners LLC owned […] - 2025-04-18 05:06:56

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. trimmed its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,401 shares of the biopharmaceutical company’s stock after selling 35,200 shares during the […] - 2025-04-09 04:51:00

Fate Therapeutics (NASDAQ:FATE) Lowered to “Sell” Rating by StockNews.com

StockNews.com cut shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating in a research note issued to investors on Tuesday. FATE has been the topic of a number of other reports. Stifel Nicolaus cut their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” […] - 2025-03-12 04:42:57

Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating

Fate Therapeutics (NASDAQ:FATE – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research firms have also issued reports on FATE. Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on […] - 2025-03-05 04:52:57

iShares Healthcare Innovation UCITS ETF USD (Acc) FATE holdings

Share Trades of FATE by Blackrock for IE00BYZK4776

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-06-11	SELL	-554	1.550	1.740	1.721	USD -953	1.52 Loss of -111 on sale
2025-05-30	SELL	-561	1.210	1.330	1.318	USD -739	1.53 Profit of 117 on sale
2025-05-21	BUY	561	1.170	1.270	1.260	USD 707	1.54
2025-05-14	SELL	-3,354	0.960	1.090	1.077	USD -3,612	1.56 Profit of 1,625 on sale
2025-04-30	SELL	-547	1.280	1.340	1.334	USD -730	1.60 Profit of 146 on sale
2025-04-28	SELL	-545	1.250	1.310	1.304	USD -711	1.61 Profit of 166 on sale
2025-04-25	SELL	-543	1.280	1.350	1.343	USD -729	1.61 Profit of 146 on sale
2025-04-11	SELL	-3,384	1.060	1.070	1.069	USD -3,617	1.65 Profit of 1,983 on sale
2025-04-08	SELL	-2,822	0.910	0.990	0.982	USD -2,771	1.68 Profit of 1,962 on sale
2025-03-31	SELL	-1,130	0.790	0.830	0.826	USD -933	1.72 Profit of 1,016 on sale
2025-03-21	SELL	-1,130	0.910	0.940	0.937	USD -1,059	1.78 Profit of 955 on sale
2025-03-12	SELL	-566	1.010	1.030	1.028	USD -582	1.86 Profit of 468 on sale
2025-02-28	SELL	-566	1.120	1.140	1.138	USD -644	1.95 Profit of 460 on sale
2025-02-25	BUY	566	1.230	1.370	1.356	USD 767	1.99
2025-02-20	SELL	-566	1.550	1.720	1.703	USD -964	2.01 Profit of 174 on sale
2025-02-19	BUY	1,130	1.710	1.810	1.800	USD 2,034	2.02
2025-02-18	BUY	565	1.530	1.700	1.683	USD 951	2.02
2025-01-22	SELL	-565	1.340	1.370	1.367	USD -772	2.32 Profit of 537 on sale
2025-01-17	SELL	-566	1.270	1.300	1.297	USD -734	2.39 Profit of 619 on sale
2024-12-30	SELL	-1,118	1.620	1.630	1.629	USD -1,821	2.64 Profit of 1,130 on sale
2024-12-06	SELL	-515	2.650	2.650	2.650	USD -1,365	2.65 Loss of -1 on sale
2024-12-04	SELL	-517	2.560	2.750	2.731	USD -1,412	2.66 Loss of -36 on sale
2024-12-03	SELL	-1,042	2.630	2.980	2.945	USD -3,069	2.66 Loss of -294 on sale
2024-11-21	SELL	-565	2.070	2.280	2.259	USD -1,276	2.63 Profit of 209 on sale
2024-11-20	SELL	-566	2.220	2.350	2.337	USD -1,323	2.65 Profit of 178 on sale
2024-11-19	SELL	-566	2.180	2.260	2.252	USD -1,275	2.68 Profit of 242 on sale
2024-11-18	SELL	-2,168	2.270	3.500	3.377	USD -7,321	2.71 Loss of -1,456 on sale
2024-11-12	SELL	-534	2.380	2.560	2.542	USD -1,357	2.73 Profit of 99 on sale
2024-11-07	SELL	-532	2.550	2.790	2.766	USD -1,472	2.76 Loss of -1 on sale
2024-11-05	SELL	-1,068	2.680	2.810	2.797	USD -2,987	2.77 Loss of -29 on sale
2024-10-28	SELL	-534	2.870	2.870	2.870	USD -1,533	2.97 Profit of 51 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of FATE

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy